122 related articles for article (PubMed ID: 33630646)
1. The acute dose and baseline amplitude-dependent effects of CDP-choline on deviance detection (MMN) in chronic schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Choueiry J; Knott V
Exp Clin Psychopharmacol; 2022 Apr; 30(2):235-248. PubMed ID: 33630646
[TBL] [Abstract][Full Text] [Related]
2. An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
J Psychopharmacol; 2023 Apr; 37(4):381-395. PubMed ID: 36927273
[TBL] [Abstract][Full Text] [Related]
3. CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
Psychopharmacology (Berl); 2020 Dec; 237(12):3665-3687. PubMed ID: 32851421
[TBL] [Abstract][Full Text] [Related]
4. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
[TBL] [Abstract][Full Text] [Related]
5. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
[TBL] [Abstract][Full Text] [Related]
6. Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Baddeley A; Knott V
J Psychopharmacol; 2018 May; 32(5):541-551. PubMed ID: 29338621
[TBL] [Abstract][Full Text] [Related]
7. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression.
Knott V; Smith D; de la Salle S; Impey D; Choueiry J; Beaudry E; Smith M; Saghir S; Ilivitsky V; Labelle A
J Psychopharmacol; 2014 Dec; 28(12):1095-108. PubMed ID: 25315828
[TBL] [Abstract][Full Text] [Related]
8. Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study.
Knott V; Impey D; Philippe T; Smith D; Choueiry J; de la Salle S; Dort H
Hum Psychopharmacol; 2014 Sep; 29(5):446-58. PubMed ID: 25196041
[TBL] [Abstract][Full Text] [Related]
9. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
[TBL] [Abstract][Full Text] [Related]
10. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
11. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
[TBL] [Abstract][Full Text] [Related]
12. Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans.
de la Salle S; Inyang L; Impey D; Smith D; Choueiry J; Nelson R; Heera J; Baddeley A; Ilivitsky V; Knott V
Pharmacol Biochem Behav; 2019 Sep; 184():172739. PubMed ID: 31283908
[TBL] [Abstract][Full Text] [Related]
13. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
[TBL] [Abstract][Full Text] [Related]
14. Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers.
Knott V; Salle S; Smith D; Choueiry J; Impey D; Smith M; Beaudry E; Saghir S; Ilivitsky V; Labelle A
Neurosci Lett; 2015 Mar; 591():121-125. PubMed ID: 25700947
[TBL] [Abstract][Full Text] [Related]
15. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism.
Uslu G; Savci V; Buyukuysal LR; Goktalay G
Neurosci Lett; 2014 May; 569():153-7. PubMed ID: 24708927
[TBL] [Abstract][Full Text] [Related]
16. Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers.
Knott V; de la Salle S; Choueiry J; Impey D; Smith D; Smith M; Beaudry E; Saghir S; Ilivitsky V; Labelle A
Pharmacol Biochem Behav; 2015 Apr; 131():119-29. PubMed ID: 25681529
[TBL] [Abstract][Full Text] [Related]
17. Mismatch negativity latency and cognitive function in schizophrenia.
Kärgel C; Sartory G; Kariofillis D; Wiltfang J; Müller BW
PLoS One; 2014; 9(4):e84536. PubMed ID: 24740391
[TBL] [Abstract][Full Text] [Related]
18. Choline or CDP-choline alters serum lipid responses to endotoxin in dogs and rats: involvement of the peripheral nicotinic acetylcholine receptors.
Ilcol YO; Yilmaz Z; Cansev M; Ulus IH
Shock; 2009 Sep; 32(3):286-94. PubMed ID: 19060783
[TBL] [Abstract][Full Text] [Related]
19. Effects of transcranial direct current stimulation on the auditory mismatch negativity response and working memory performance in schizophrenia: a pilot study.
Impey D; Baddeley A; Nelson R; Labelle A; Knott V
J Neural Transm (Vienna); 2017 Nov; 124(11):1489-1501. PubMed ID: 28864916
[TBL] [Abstract][Full Text] [Related]
20. CDP-choline: pharmacological and clinical review.
Secades JJ; Frontera G
Methods Find Exp Clin Pharmacol; 1995 Oct; 17 Suppl B():1-54. PubMed ID: 8709678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]